Wells Fargo’s Acrivon Therapeutics ACRV Stock Holding History

Wells Fargo’s Portfolio ACRV Stock Details ACRV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-3,000	Closed	-$4.17K	–	7276
2026 Q1	$4.17K	Buy	+3,000	New	+$5.23K	﹤0.01%	6160
2025 Q3	–	Sell	-141	Closed	-$168	–	7064
2025 Q2	$168	Sell	141 -6,949	-98%	-$9.54K	﹤0.01%	6450
2025 Q1	$14.4K	Buy	7,090 +157	+2%	+$845	﹤0.01%	5799
2024 Q4	$41.7K	Buy	6,933 +1,511	+28%	+$11K	﹤0.01%	5547
2024 Q3	$38K	Buy	5,422 +231	+4%	+$1.82K	﹤0.01%	5447
2024 Q2	$30.1K	Buy	5,191 +892	+21%	+$7.18K	﹤0.01%	5465
2024 Q1	$30.7K	Buy	4,299 +1,608	+60%	+$7.46K	﹤0.01%	5441
2023 Q4	$13.2K	Buy	2,691 +530	+25%	+$2.8K	﹤0.01%	5754
2023 Q3	$20.7K	Sell	2,161 -1,144	-35%	-$13.2K	﹤0.01%	5584
2023 Q2	$42.8K	Buy	3,305 +1,717	+108%	+$20.8K	﹤0.01%	5488
2023 Q1	$20.2K	Buy	+1,588	New	+$26.7K	﹤0.01%	5635

Other funds holding ACRV

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

SCV

Sands Capital Ventures Arlington, Virginia $614M AUM 19.92% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $5.69B AUM 60.64% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Wells Fargo's ACRV Position: Q2 2026 in Review

Wells Fargo sold out of Acrivon Therapeutics (ACRV) in Q2 2026, closing a stake of 3,000 shares — an estimated $4.17K sold.

Wells Fargo first reported a position in ACRV in Q1 2023 and held it in 11 quarters. The position peaked at $42.8K in Q2 2023. 46 funds tracked by Wall St. Rank hold ACRV as of Q2 2026.

Wells Fargo reported no remaining Acrivon Therapeutics position as of Q2 2026 after selling out during the quarter.
Wells Fargo sold 3,000 Acrivon Therapeutics shares in Q2 2026, an estimated $4.17K.
Wells Fargo first reported a position in Acrivon Therapeutics in Q1 2023 and held it in 11 quarters.
Wells Fargo's Acrivon Therapeutics position peaked at $42.8K in Q2 2023.
46 funds tracked by Wall St. Rank held Acrivon Therapeutics as of Q2 2026.

Based on Wells Fargo's 13F filing for Q2 2026, filed 14 Aug 2026.